# Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

> **NCT03245151** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 64 (actual)

## Conditions studied

- Recurrent and Refractory Solid Tumors

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT03245151
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-16
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2023-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03245151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03245151, "Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03245151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*